Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-06-14Est. Completion: 2030-06-30
Enrollment target: 57 participants
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States